Dr. Lal Path Labs , a leading diagnostic and related healthcare service provider, has made significant announcements regarding shareholder benefits, including the confirmation of key dates for its bonus share issue.

Bonus Share Issue - Key Dates Confirmed

The Board of Directors has fixed December 19, 2025 as the record date for determining shareholder eligibility for the bonus share issue. The company announced a bonus share issue in the ratio of 1:1, meaning shareholders will receive one new fully paid-up equity share for every existing share they hold.

The deemed date of allotment for bonus equity shares has been set as December 22, 2025, in accordance with SEBI circular no. CIR/CFD/PoD/2024/122 dated September 16, 2024.

Second Interim Dividend Declaration

The Board of Directors, in their meeting held on October 31, 2025, approved a second interim dividend of ₹7.00 per equity share. This dividend represents 70% of the face value of ₹10.00 per share for the financial year 2025-26.

Authorized Share Capital Enhancement

To facilitate the bonus issue, the company has increased its authorized share capital from ₹1,07,96,00,000 to ₹2,00,00,00,000, subject to shareholders' approval. The bonus shares will be issued from the company's Securities Premium Account, which stood at ₹1,247.85 million as per the audited financial statements for the year ended March 31, 2025.

Recent Financial Performance

For the quarter ended September 30, 2025, Dr. Lal PathLabs reported consolidated revenue of ₹7,548.00 million and profit after tax of ₹1,333.00 million.

The company expects to credit/dispatch the bonus shares within two months from the date of board approval, i.e., by December 30, 2025. Shareholders whose names appear in the Register of Members or List of Beneficial Owners as received from NSDL and CDSL on the record date will be eligible for the bonus shares.

Dr. Lal Path Labs , a leading diagnostic and healthcare service provider, has reported strong financial results for the second quarter, along with an announcement of a bonus share issue.

Q2 Financial Highlights

Dr. Lal PathLabs has demonstrated robust growth in its Q2 performance:

The company maintained a healthy EBITDA margin of 30.7%, showcasing its operational efficiency.

Bonus Share Announcement

The Board of Directors has approved a bonus share issue in the ratio of 1:1. This means shareholders will receive one new fully paid-up equity share for every existing share held.

Key details of the bonus issue include:

• Ratio: 1:1 (One bonus share for each existing share)
• Face Value: INR 10 per share
• Eligibility: Shareholders as of the yet-to-be-announced record date
• Issuance: Subject to shareholder and regulatory approvals

Additional Corporate Actions

The company has also declared other significant corporate actions:

1. Interim Dividend: A second interim dividend of INR 7 per equity share (70% on face value of INR 10) for the financial year 2025-26.

2. Increase in Authorized Share Capital: The company plans to increase its authorized share capital from INR 1,07,96,00,000 to INR 2,00,00,00,000, subject to shareholder approval.

3. Employee Stock Option Plan: Introduction of "Dr. Lal PathLabs Employee Restricted Stock Unit Plan 2025" (RSU 2025), allocating options from the existing Employee Stock Option Plan 2022.

Market Implications

The combination of strong financial performance and shareholder-friendly actions like the bonus issue may potentially boost investor confidence in Dr. Lal PathLabs. The bonus issue could increase the liquidity of the stock without affecting the company's valuation.

As the healthcare sector continues to be a focus area for investors, Dr. Lal PathLabs' performance and strategic decisions may be closely watched by market participants for indications of broader sector trends.

Investors and shareholders should note that the record date for the bonus issue and other corporate actions will be announced in due course, and all actions are subject to necessary approvals.